Myelodysplastic Syndromes (MDS)

Dr. Traer completed a fellowship in hematology/oncology from Oregon Health & Science University. He received his M.D./Ph.D. from the University of Texas Southwestern Medical School and completed a residency in internal medicine at Oregon Health & Science University. In addition to practicing general hematology at OHSU Knight Cancer Institute, Dr. Traer is involved in clinical trials evaluating targeted therapy with kinase inhibitors in leukemia patients. He is performing research with Brian Druker, M.D. to investigate how the bone marrow microenvironment provides sanctuary to leukemia cells by

Dr. Naval Daver is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. He completed his medical school from Grant Medical College and Sir J group of Hospitals Mumbai, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in AML and Myelofibrosis and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases.

Graduated in Medicine (1997) and PhD in Clinical Medicine (2003) from the Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP) and medical residency in Hematology and Hemotherapy (2001) from the Hospital das Clinicas of FMRP-USP. He did postdoctoral studies at the National Institutes of Health, Bethesda, Maryland, USA, where he also worked as a Staff Scientist at the Hematology Branch until 2011. He is currently an Associate Professor in the Department of Clinical Medicine at FMRP-USP, coordinator of the Hematology and Program discipline Graduate Program in Oncology, Stem